DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM) has earned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eighteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $83.50.

DXCM has been the subject of a number of analyst reports. Wall Street Zen raised DexCom from a “buy” rating to a “strong-buy” rating in a report on Saturday. Canaccord Genuity Group set a $100.00 price objective on DexCom and gave the company a “buy” rating in a report on Friday. Truist Financial reissued a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a report on Tuesday, March 24th. Finally, Piper Sandler reissued an “overweight” rating on shares of DexCom in a report on Thursday, February 5th.

Insider Activity

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after buying an additional 1,133,638 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of DexCom by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after buying an additional 42,411 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of DexCom by 6.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after buying an additional 516,526 shares during the last quarter. Norges Bank bought a new position in shares of DexCom in the fourth quarter valued at about $483,356,000. Finally, Invesco Ltd. raised its holdings in shares of DexCom by 14.8% in the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after buying an additional 686,228 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Down 2.1%

DXCM opened at $60.04 on Tuesday. DexCom has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm’s fifty day moving average price is $65.87 and its two-hundred day moving average price is $66.41. The company has a market capitalization of $23.17 billion, a P/E ratio of 25.66, a P/E/G ratio of 1.18 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business’s revenue was up 15.0% on a year-over-year basis. During the same period last year, the business earned $0.32 earnings per share. On average, analysts anticipate that DexCom will post 2.52 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.